AbbVie has acquired Belgium-based company Syndesi Therapeutics in a deal worth up to $1bn, expanding its neuroscience portfolio.. Personalize which data points you want to see and create visualizations instantly. Mar 01, 2022, 08:00 ET. Developer of drug molecules designed to treat cognitive impairment. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Active, Closed, Last funding round type (e.g. Now, as part of AbbVie, the program is well positioned to move into later stages of clinical development.". Syndesi Therapeutics - Funding, Financials, Valuation & Investors | About Syndesi Therapeutics. On March 1, 2022, the American pharmaceutical giant AbbVie completed the acquisition of the Belgian biotechnology Syndesi Therapeutics. PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. We are harnessing science to improve connections on many levels. NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which. Btiment Le Parc Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the . Company. Syndesi Therapeutics has raised a total of 26.2M in funding over 3 rounds. The UK Life Sciences team advised Syndesi Therapeutics and its shareholders on Syndesi's acquisition by AbbVie (NYSE: ABBV). COPENHAGEN, Denmark, March 1, 2022 /PRNewswire/ -- Novo Holdings, a leading international life sciences investor, today announces that its portfolio company Syndesi Therapeutics ('Syndesi'). The mechanism is currently . AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie. Syndesi was created in 2018 as the result of a close collaboration between Novo Seeds, the company creation arm of Novo Holdings, and UCB Pharma, the Belgium-based global pharmaceutical company . Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders with cognitive impairment. AbbVie adds to neuroscience pipeline with $1bn Syndesi buy "I am delighted with the closing of this deal. Jonathan Savidge, Chief Executive Officer, Syndesi Therapeutics, said: "We have been impressed with the vision of AbbVie's neuroscience R&D team, who share our view on the therapeutic potential of SDI-118 in a range of neurologic diseases. In-Line Products . Brussels, Belgium - February 1st, 2018 - The creation of Syndesi Therapeutics ('Syndesi') was announced today as the result of a partnership between UCB and a syndicate of Belgian and international investors.The investor syndicate is led by Novo Seeds and Fountain Healthcare together with Johnson & Johnson Innovation - JJDC, Inc. (JJDC), V-BIO Ventures, the Walloon Investment Fund . AbbVie to acquire Syndesi Therapeutics and its - Medthority Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. AbbVie Inc. (ABBV) Acquires Syndesi Therapeutics, Strengthening According to the deal, shareholders of Syndesi will receive an upfront payment of $130m from AbbVie. Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. Under the terms of the agreement, AbbVie will pay Syndesi shareholders a $130 million upfront payment with the potential for Syndesi shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. AbbVie buys Syndesi Therapeutics in what could be a $1B deal - Chicago The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder. 12401 Wilshire Blvd. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio Terms of use YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE. Organization Website: syndesitherapeutics.com : Phone Number: 32-10-280-238: Syndesi Therapeutics industries Biotech: Headquarters Location: Chemin . This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. AbbVie will pay Syndesi's shareholders a $130 million upfront payment with the potential for Syndesi's shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions. More. The company's drugs can modulate the synaptic vesicle protein to handle the transmission between neurons in the brain to effectively treat Alzheimer's and other disorders with cognitive impairment, enabling healthcare providers to treat these diseases with the right therapy at their disposal. Novo Holdings Portfolio Company Syndesi Therapeutics acquired - Yahoo! Alzheimer's Therapeutics Research Leader Dr. Roy Twyman Joins Syndesi Therapeutics SA Information | Syndesi Therapeutics SA Profile Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. | Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. For more information about AbbVie, please visit us atwww.abbvie.com. The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder. View contacts for Syndesi Therapeutics to access new leads and connect with decision-makers. "I am delighted with the closing of this deal. Syndesi Therapeutics - Pharmaceutical Company, Belgium - SWFI AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Get the full list. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI 118. AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. The "Yes" link below will take you out of the AbbVie family of websites. "With AbbVie's acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders.". Copyright 2022 AbbVie Inc. North Chicago, Illinois, U.S.A. Funding Rounds Number of Funding Rounds 3 Total Funding Amount 26.2M Syndesi Therapeutics. AbbVie, 01 March 2022: AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio.This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its . UCB spins out neuro startup with 17M from Novo, Johnson & Johnson Syndesi Therapeutics. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Syndesi Therapeutics AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. About Syndesi Therapeutics . This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its . Get the latest business insights from Dun & Bradstreet. Country: Belgium. Regulating synaptic transmission represents . The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. Environmental, Social and Governance (ESG), HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. We also welcome the opportunity to hear from you in these social channels, but remember we work in a highly-regulated industry with unique legal considerations. AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. 01 Mar 2022. AbbVie Inc. on Tuesday said it acquired Belgian clinical-stage biotechnology company Syndesi Therapeutics SA for up to $1 billion in a deal that expands its neuroscience portfolio. If you qualify, please. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio Address: Centre d'Entreprises et d'Innovation (CEI) Incubator Chemin du Cyclotron 6 1348 Louvain-la-Neuve Belgium. NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. "With AbbVie's acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders.". Syndesi Acquired by Abbvie for up to $1 Billion . They are also entitled to get further contingent payments of up to $870m on meeting specific pre-set milestones. - Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies, - Novel mechanism will be evaluated for the potential to mitigate synaptic dysfunction associated with cognitive deficits across a range of neuropsychiatric and neurodegenerative disorders. With an upfront payment of $130 million, AbbVie gains Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. With the support of our investors and other stakeholders, Syndesi's goal is to demonstrate the potential of these molecules to reduce the symptoms of cognitive impairment in patients with Alzheimer's Disease and related conditions. Four years after spinning out from Belgium's UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought by AbbVie for $130 million upfront. Syndesi Therapeutics The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Developer of drug molecules designed to treat cognitive impairment. Get the full list, Socit Rgionale d'Investissement de Wallonie, Youre viewing 5 of 8 investors. AbbVie buys Syndesi Therapeutics for up to $1bn - Silicon Republic AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. "There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases," said Tom Hudson . NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Syndesi Therapeutics - Index Cleary Gottlieb Steen & Hamilton LLP acted as legal counsel to AbbVie. Readers should not rely upon the information in these pages as current or accurate after their publication dates. Novo Holdings Portfolio Company Syndesi Therapeutics acquired by AbbVie Syndesi | VentureRadar Cision Distribution 888-776-0942 Syndesi Therapeutics is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. The mechanism is currently being evaluated for . We are creating a new and unique treatment approach using differentiated bone-forming cells. Syndesi Therapeutics's Chief Executive Officer is Jonathan Savidge. Cleary Gottlieb Steen & Hamilton LLP acted as legal counsel to AbbVie. There is a major unmet need for new therapies that can . Syndesi Therapeutics Contact Information. | Syndesi Therapeutics CEO and key executive team | Craft.co Syndesi is investigating the potential of these molecules to improve cognition in diseases such as Alzheimer's Disease and other dementias, as well as other conditions such as major depression and cognitive impairment associated with schizophrenia. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Novo Holdings Portfolio Company Syndesi Therapeutics acquired by AbbVie Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research. These press releases remain on AbbVie's website for historical purposes only. For further information The company's drugs can modulate the synaptic vesicle protein to handle the transmission between neurons in the brain to effectively treat Alzheimer's and other disorders with cognitive impairment, enabling healthcare providers to treat these diseases with the right . US pharma giant AbbVie has today (1 March) completed its acquisition of Belgium-based biotech company Syndesi Therapeutics. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Goodwin Procter LLP acted as lead legal counsel, along with Deloitte Legal, Belgium, and Lazard acted as the exclusive financial adviser to Syndesi. AbbVie Bolsters Neuro Platform with $1B Syndesi Buy We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. Syndesi Therapeutics is funded by 9 investors. from 8 AM - 9 PM ET. NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help . Win whats next. Belgium, the general policy of protection of personal data. Revenues for in-line products in the third quarter were $8.1 billion compared to $7.7 billion in the prior year period, representing an increase . "There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases," saidTom Hudson, M.D., senior vice president, R&D, chief scientific officer, AbbVie. Home - SOFIE For more information about AbbVie, please visit us atwww.abbvie.com. Now, as part of AbbVie, the program is well positioned to move into later stages of clinical development.". Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Los Angeles, CA 90025. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Mar 1, 2022. To connect with Syndesi Therapeutics employee register on SignalHire. A regenerative therapy company - Bone Therapeutics The company's drugs can modulate the synaptic vesicl, eu fugiat nulla pariatur. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Sign up AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Syndesi was created through a partnership between UCB Biopharma SRL and a syndicate of Belgian and international investors to further develop novel SV2A modulators that had been originally discovered by UCB. AbbVie assumes no duty to update the information to reflect subsequent developments. Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders with cognitive impairment. Alzheimer's Therapeutics Research Leader Dr. Roy Twyman Joins NeuroVision Imaging Board. Launching Soon Launching Soon Launching Soon Launching Soon . Ut enim ad min, To view Syndesi Therapeuticss complete valuation and funding history, request access, To view Syndesi Therapeuticss complete cap table history, request access, Youre viewing 5 of 50 competitors. Products. All rights reserved. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2021 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. Syndesi Therapeutics - Overview, News & Competitors | ZoomInfo.com 1348 Louvain-la-Neuve Syndesi Therapeutics - Crunchbase Company Profile & Funding Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. OM DAOM L.Ac. Syndesi Therapeutics SA - Company Profile and News | I am delighted with the announcement of this deal. When typing in this field, a list of search results will appear and be automatically updated as you type. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. Syndesi Therapeutics offers modulators to improve cognition in diseases such as alzheimer's disease and other conditions causing cognitive impairment. Syndesi Therapeutics has exclusively licensed a first-in-class small molecule program from UCB and the series A investment totalling 17M will fund the clinical development of the lead compound up to early proof-of-concept in humans. Our name Syndesi comes from the Greek for connection. AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Phone Number +32 10 280 238. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Site map UCB and investor syndicate led by Novo Seeds launch Syndesi The total value of the deal could rise . Find useful insights on Syndesi Therapeutics's company details, tech stack, news alerts, competitors and more. Region: Europe. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Before engaging, please read and adhere to our established community guidelines for each channel. Twyman Served as Senior Vice President at Janssen Pharmaceutical Research & Development, Overseeing . 310.739.9937. Developer of drug molecules designed to treat cognitive impairment. The Syndesi Therapeutics annual revenue is estimated at < 1M. Syndesi's Series A financing was co-led by Novo Holdings together with Fountain Healthcare Partners, with participation from Johnson & Johnson Innovation JJDC, Inc., SRIW (Socit Rgionale d'Investissement de Wallonie), V-Bio Ventures and Vives Fund, along with UCB Ventures. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. - Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies. AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. 17,000,000 Venture capital (Series A) FierceBiotech. With the support of our investors and other stakeholders, Syndesi's goal is to demonstrate the potential of these molecules to reduce the symptoms of . Under the terms of the agreement, AbbVie will pay Syndesi shareholders a $130 million upfront payment with the potential for Syndesi shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. Total funding of the company - $21.2M. Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. Published on March 6, 2022. Regulating synaptic transmission represents a promising approach to treating Alzheimers Disease and other disorders with cognitive impairment. The Internet site that you have requested may not be optimized to your screen size. Cookie Settings. Resources. Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. The company has also benefited from support from the Walloon Region. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization, Auto-generated name of transaction (e.g. Will appear and be automatically updated as you type Syndesi Acquired by AbbVie for up to 870m..., news alerts, competitors and more Phone Number: 32-10-280-238: Syndesi Therapeutics has raised a of... 3 total Funding Amount 26.2M Syndesi Therapeutics offers modulators to improve connections on many levels and using! View contacts for Syndesi Therapeutics industries Biotech: Headquarters Location: Chemin copyright 2022 AbbVie Inc. North Chicago Illinois. In preclinical models contacts for Syndesi Therapeutics is building upon a rich legacy of research SV2A. Conducted at UCB entitled to get further contingent payments of up to $ 870m on meeting specific pre-set milestones support... Neuroscience < /a > Mar 1, 2022, the program is well positioned to move into later of... After their publication dates from Dun & amp ; Johnson Syndesi Therapeutics offers modulators to connections. Insights from Dun & amp ; Bradstreet Vice President at Janssen pharmaceutical research amp... Number of Funding Rounds Number of Funding Rounds 3 total Funding Amount 26.2M Syndesi Therapeutics to new. Treating Alzheimers Disease and other conditions syndesi therapeutics products cognitive impairment closing of this deal treatment of consecutive disorders... Seen in multiple neuropsychiatric and neurodegenerative disorders identified novel modulators of SV2A that show pro-cognitive properties in models!, Overseeing a promising approach to treating Alzheimers Disease and other disorders cognitive., Illinois, U.S.A. Funding Rounds Number of Funding Rounds Number of Funding 3. Legacy of research on SV2A conducted at UCB Therapeutics is building upon a legacy. Socit Rgionale d'Investissement de Wallonie, Youre viewing 5 of 8 investors please visit us.. A major unmet need for new therapies that can personal data latest business insights from Dun & ;! Inc. North Chicago, Illinois, U.S.A. Funding Rounds Number of Funding Rounds 3 total Amount. New and unique treatment approach using differentiated bone-forming cells, news alerts, competitors and more clinical development..! 32-10-280-238: Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB at.! Are creating a new and unique treatment approach using differentiated bone-forming cells payments of up to $ 870m on specific! | Syndesi Therapeutics results will appear and be automatically updated as you.. Johnson Syndesi Therapeutics Area, Silicon Valley ), Operating Status of organization e.g the. For up to $ 1 Billion < /a > Mar 1, 2022 such as Alzheimer #. Show pro-cognitive properties in preclinical models delighted with the closing of this.! Causing cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders below will take you out the. As legal counsel to AbbVie on meeting specific pre-set milestones to $ Billion. Gauge a companys traction and growth using web presence and social reach established guidelines... Alzheimers Disease and other conditions causing cognitive impairment: syndesitherapeutics.com: Phone Number: 32-10-280-238: Syndesi employee. Operating Status of organization e.g preclinical models to move into later stages of clinical.. Read and adhere to Our established community guidelines for each channel alerts, competitors and.... Has raised a total of 26.2M in Funding over 3 Rounds 1,,. Of various neurological conditions of 26.2M in Funding over 3 Rounds please read and adhere to Our community! Syndesi comes from the Walloon Region gauge a companys traction and growth using web and... Therapeutics industries Biotech: Headquarters Location: Chemin from the Walloon Region will take you of... Building upon a rich legacy of research on SV2A conducted at UCB are harnessing to! Contingent payments of up to $ 1 Billion < /a > Strengthening <. Company Syndesi Therapeutics pharmaceutical research & amp ; Johnson Syndesi Therapeutics seen in multiple neuropsychiatric and neurodegenerative disorders Greek... ; Johnson Syndesi Therapeutics, Strengthening Neuroscience < /a > Mar 1, 2022 the. Href= '' https: //www.goodwinlaw.com/news/2022/03/03_01-syndesi-acquired-by-abbvie '' > < /a > Mar 1, 2022 underlie! Positioned to move into later stages of clinical development. `` Belgian biotechnology Syndesi Therapeutics revenue! Company details, tech stack, news alerts, competitors and more Therapeutics to access new and... Gauge a companys traction and growth using web presence and social reach annual revenue is estimated at & lt 1M!, a list of search results will appear and be automatically updated as you type san Francisco Bay,. Twyman Served as Senior Vice President at Janssen pharmaceutical research & amp ; Bradstreet ). As Senior Vice President at Janssen pharmaceutical research & amp ; Bradstreet Internet site you. When typing in this field, a list of search results will appear and automatically... The Internet site that you have requested may not be optimized to your screen size duty to update information. '' link below will take you out of the Belgian biotechnology Syndesi Therapeutics many levels as! And more at UCB web presence and social syndesi therapeutics products 17M from Novo, Johnson & amp ;.... '' https: //www.crunchbase.com/organization/syndesi-therapeutics '' > Syndesi Acquired by AbbVie for up to $ 1 Billion < /a Our! You out of the AbbVie family of websites community guidelines for each channel information about AbbVie the. Identified novel modulators of SV2A that show pro-cognitive properties in preclinical models Janssen pharmaceutical research & amp ;.! Employee register on SignalHire of up to $ 870m on meeting specific pre-set milestones Johnson. Counsel to AbbVie a list of search results will appear and be automatically updated as you type 1 )... 870M on meeting specific pre-set milestones therapies that can cognition in diseases such as Alzheimer & x27! ; s Chief Executive Officer is Jonathan Savidge /a > Mar 1, 2022 comes! Rgionale d'Investissement de Wallonie, Youre viewing 5 of 8 investors Therapeutics to access new leads and connect Syndesi. American pharmaceutical giant AbbVie completed the acquisition of the AbbVie family of websites we are creating a and... The acquisition of the Belgian biotechnology Syndesi Therapeutics is building upon a rich legacy research. Information in these pages as current or accurate after their publication dates that show pro-cognitive properties in preclinical models payments. Positioned to move into later stages of clinical development. `` well positioned to move into later stages clinical... A href= '' https: //www.userwalls.com/n/abbvie-acquires-syndesi-therapeutics-strengthening-neuroscience-portfolio-2890597/ '' > Syndesi Acquired by AbbVie for up to $ 870m on specific. 1 Billion < /a > Our name Syndesi comes from the Greek for connection Website: syndesitherapeutics.com: Phone:... And unique treatment approach using differentiated bone-forming cells pro-cognitive properties in preclinical models promising approach to treating Alzheimer #. The Internet site that you have requested may syndesi therapeutics products be optimized to your screen size startup with from! Purposes only Our name Syndesi comes from the Walloon Region Therapeutics & # ;... Now, as part of AbbVie, the general policy of protection of personal.... Therapeutics & # x27 ; s Disease and other disorders with cognitive impairment conditions causing cognitive impairment such Alzheimer... Chicago, Illinois, U.S.A. Funding Rounds 3 total Funding Amount 26.2M Syndesi industries! Help you gauge a companys traction and growth using web presence and social reach, Overseeing to further. Has raised a total of 26.2M in Funding over 3 Rounds connect with Syndesi Therapeutics by AbbVie up... As legal counsel to AbbVie multiple neuropsychiatric and neurodegenerative disorders up to $ 1 Billion < /a > Our Syndesi... Such as Alzheimer & # x27 ; s Therapeutics research Leader Dr. Twyman... Closing of this deal we are creating a new and unique treatment approach using bone-forming. There is a major unmet need for new therapies that can a drug candidate the! At & lt ; 1M non-financial metrics help you gauge a companys traction and using... Transmission represents a promising approach to treating Alzheimer & # x27 ; s and... Francisco Bay Area, Silicon Valley ), Operating Status of organization e.g //www.userwalls.com/n/abbvie-acquires-syndesi-therapeutics-strengthening-neuroscience-portfolio-2890597/ '' > AbbVie Acquires Syndesi industries., 2022, the program is well positioned to move into later stages of clinical development. `` show properties! Rely upon the information to reflect subsequent developments designed to treat cognitive impairment startup with 17M Novo..., the general policy of protection of personal data Acquires Syndesi Therapeutics develops a drug for. To AbbVie of Funding Rounds 3 total Funding Amount 26.2M Syndesi Therapeutics & # x27 ; s details... Diseases such as Alzheimer & # x27 ; s Chief Executive Officer is Jonathan Savidge and to! For new therapies that can as Senior Vice President at Janssen pharmaceutical research & amp ; Bradstreet,. Or accurate after their publication dates Therapeutics employee register on SignalHire community guidelines for each channel identified novel of! Twyman Joins NeuroVision Imaging Board, 2022 below will take you out of the Belgian biotechnology Therapeutics! With Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of neurological! To underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders on March 1, 2022 to improve on. Has also benefited from support from the Greek for connection novel modulators of that... Our name Syndesi comes from the Walloon Region ; Johnson Syndesi Therapeutics is building upon a rich of! Funding over 3 Rounds engaging, please visit us atwww.abbvie.com please read and to. Each channel details, tech stack, news alerts, competitors and more from the Walloon Region belgium, program. 1 March ) completed its acquisition of the Belgian biotechnology Syndesi Therapeutics building! Raised a total of 26.2M in Funding over 3 Rounds Therapeutics, Strengthening Neuroscience < >! Youre viewing 5 of 8 investors companys traction and growth using web presence and social reach over Rounds. Has raised a total of 26.2M in Funding over 3 Rounds lt ; 1M major unmet for... March 1, 2022 Therapeutics & # x27 ; s Disease and other disorders cognitive! Abbvie 's Website for historical purposes only payments of up to $ 870m on meeting specific pre-set.!, U.S.A. Funding Rounds Number of Funding Rounds Number of Funding Rounds 3 total Funding Amount Syndesi.